GlaxoSmithKline PLC (NYSE:GSK) major shareholder Plc Glaxosmithkline purchased 428,571 shares of the business’s stock in a transaction on Monday, November 6th. The shares were bought at an average cost of $14.00 per share, for a total transaction of $5,999,994.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Large shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Shares of GlaxoSmithKline PLC (GSK) opened at $35.77 on Friday. The stock has a market cap of $89,715.84, a P/E ratio of 12.94, a PEG ratio of 2.02 and a beta of 1.00. The company has a current ratio of 0.64, a quick ratio of 0.44 and a debt-to-equity ratio of 2.96. GlaxoSmithKline PLC has a 1-year low of $35.57 and a 1-year high of $44.53.

The business also recently announced a quarterly dividend, which will be paid on Thursday, January 11th. Investors of record on Friday, November 10th will be issued a $0.5037 dividend. This represents a $2.01 annualized dividend and a yield of 5.63%. The ex-dividend date is Thursday, November 9th. This is an increase from GlaxoSmithKline PLC’s previous quarterly dividend of $0.49. GlaxoSmithKline PLC’s dividend payout ratio (DPR) is 162.30%.

COPYRIGHT VIOLATION NOTICE: This story was reported by Daily Political and is owned by of Daily Political. If you are accessing this story on another domain, it was illegally stolen and republished in violation of international trademark & copyright legislation. The original version of this story can be viewed at https://www.dailypolitical.com/2017/11/10/glaxosmithkline-plc-gsk-major-shareholder-purchases-5999994-00-in-stock.html.

A number of equities research analysts have recently commented on GSK shares. Zacks Investment Research upgraded GlaxoSmithKline PLC from a “hold” rating to a “buy” rating and set a $46.00 target price on the stock in a research report on Wednesday, October 18th. Morgan Stanley cut GlaxoSmithKline PLC from an “equal weight” rating to an “underweight” rating in a research report on Friday, September 8th. Argus restated a “buy” rating and set a $50.00 target price on shares of GlaxoSmithKline PLC in a research report on Thursday, August 31st. TheStreet upgraded GlaxoSmithKline PLC from a “c+” rating to a “b” rating in a research report on Wednesday, October 25th. Finally, BidaskClub upgraded GlaxoSmithKline PLC from a “strong sell” rating to a “sell” rating in a research report on Friday, August 25th. Three investment analysts have rated the stock with a sell rating, ten have issued a hold rating and five have issued a buy rating to the company. GlaxoSmithKline PLC currently has a consensus rating of “Hold” and an average price target of $44.33.

Institutional investors have recently bought and sold shares of the stock. Proficio Capital Partners LLC increased its holdings in GlaxoSmithKline PLC by 233.0% in the 1st quarter. Proficio Capital Partners LLC now owns 2,844 shares of the pharmaceutical company’s stock valued at $122,000 after purchasing an additional 1,990 shares during the last quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA increased its holdings in GlaxoSmithKline PLC by 1.9% in the 2nd quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA now owns 3,374 shares of the pharmaceutical company’s stock valued at $137,000 after purchasing an additional 64 shares during the last quarter. FTB Advisors Inc. increased its holdings in GlaxoSmithKline PLC by 16.9% in the 2nd quarter. FTB Advisors Inc. now owns 3,735 shares of the pharmaceutical company’s stock valued at $146,000 after purchasing an additional 539 shares during the last quarter. Advisory Services Network LLC increased its holdings in GlaxoSmithKline PLC by 24.2% in the 2nd quarter. Advisory Services Network LLC now owns 4,047 shares of the pharmaceutical company’s stock valued at $175,000 after purchasing an additional 788 shares during the last quarter. Finally, Parallel Advisors LLC increased its holdings in GlaxoSmithKline PLC by 93.4% in the 2nd quarter. Parallel Advisors LLC now owns 4,048 shares of the pharmaceutical company’s stock valued at $164,000 after purchasing an additional 1,955 shares during the last quarter. Hedge funds and other institutional investors own 9.29% of the company’s stock.

GlaxoSmithKline PLC Company Profile

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Receive News & Ratings for GlaxoSmithKline PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline PLC and related companies with MarketBeat.com's FREE daily email newsletter.